Increasing demand for safe and easy-to-use medication distribution devices and attempts by healthcare providers to reduce human errors in drug delivery accidents are primary growth driving forces for the industry.
According to a recent analysis by Emergen Research, the worldwide cell culture market is anticipated to reach USD 45.12 billion by 2027. Some of the factors boosting demand for the cell culture sector include rising demand for monoclonal antibodies, a growing focus on personalised medicines, and rising support for cell-based investigations. Business demand has been sparked by the growing body of knowledge regarding the advantages of cell culture-based vaccinations. As a result, market growth is being driven by the growing use of battery culture-based vaccinations to treat illnesses.
The market is also growing as doctors and patients become more knowledgeable about the uses of monoclonal antibody therapy. Monoclonal antibodies, which are beginning to develop for sanitary conditions and some diseases, have been among the most innovative biological medications to hit the market.
Because building up cell culture infrastructure is expensive and requires specialised knowledge, there is likely to be an increase in the demand for the cytological services offered by contract research businesses. Furthermore, because of the significant sums of money invested in this field, research into regeneration medicine has experienced great progress in recent years. Since cell culture methods are a crucial stage in these research applications, the market is anticipated to experience rapid expansion in the near future.
The global Cell Culture market report studies the prudent tactics undertaken by the leading market players, such as partnerships and collaborations, mergers & acquisitions, new product launches, and joint ventures.
Due to the dominance of mammalian cell cultures in the production of mammalian pharmaceuticals and the rising demand for non-conventional drugs produced as a result of the bio-production of proteomically ally and genetically enhanced drugs, the biopharmaceutical application of the North American region is the major shareholder of the market and held approximately 29.2% of the market in the year 2019.
Some of the key participants in this industry include:
- Thermo Fisher Scientific Inc.,
- Cell Culture Company LLC,
- Sigma-Aldrich Co. LLC,
- Corning Incorporated,
- Dickinson & Company,
- VWR International LLC,
- BioSpherix Ltd.,
- General Electric,
- Sartorius AG, and
- Merck KGaA
The major market participants are making efforts to diversify their product offerings and improve their market positioning. For instance, in January 2022, Nucleus Biologics and Cytiva (Danaher Corporation) worked together to produce specialised culture media for cell and gene therapies. In order to increase their market position, new firms are also expanding their current service offerings. For instance, KromaTiD increased the range of services it offered in February 2022 by including cell and blood culture isolation, processing, and quality control services.
The adoption of cell culture technology is also anticipated to be fueled by ongoing developments in regenerative medicine and the significant unmet medical needs in emerging economies. Government programmes in this area are also helping the sector expand. For instance, India’s Union Health Ministry changed the Novel Pharmaceuticals & Clinical Trials Rules in January 2022 to include goods created from cells or stem cells as new drugs. This gave the nation’s cell-derived product manufacturing a strong regulatory framework, which is likely to have a good impact on the industry’s expansion.
For the purpose of this report, Emergen Research has segmented the global Cell Culture Market on the basis of Consumables, Product, Application, and region:
Consumables Outlook (Revenue, USD Billion; 2017-2027)
Product Outlook (Revenue, USD Billion; 2017-2027)
- Culture Systems
- Pipetting Instruments
- Biosafety Equipment
- Cryostorage Equipment
Application Outlook (Revenue, USD Billion; 2017-2027)
- Cancer Research
- Vaccine Production
- Drug Development
· Gene Therapy